EE04589B1 - Vähivastaste ühendite valmistamise protsessid ja vaheühendid - Google Patents

Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Info

Publication number
EE04589B1
EE04589B1 EEP200000255A EEP200000255A EE04589B1 EE 04589 B1 EE04589 B1 EE 04589B1 EE P200000255 A EEP200000255 A EE P200000255A EE P200000255 A EEP200000255 A EE P200000255A EE 04589 B1 EE04589 B1 EE 04589B1
Authority
EE
Estonia
Prior art keywords
intermediates
processes
preparation
anticancer compounds
anticancer
Prior art date
Application number
EEP200000255A
Other languages
English (en)
Estonian (et)
Inventor
Shelton Lehner Richard
Norris Timothy
Paul Santafianos Dinos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200000255A publication Critical patent/EE200000255A/xx
Publication of EE04589B1 publication Critical patent/EE04589B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Metallurgy (AREA)
  • Mechanical Engineering (AREA)
  • Materials Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200000255A 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid EE04589B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (2)

Publication Number Publication Date
EE200000255A EE200000255A (et) 2000-12-15
EE04589B1 true EE04589B1 (et) 2006-02-15

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000255A EE04589B1 (et) 1999-03-31 2000-03-30 Vähivastaste ühendite valmistamise protsessid ja vaheühendid

Country Status (49)

Country Link
US (1) US6476040B1 (fr)
EP (1) EP1044969B1 (fr)
JP (2) JP3420549B2 (fr)
KR (2) KR100430210B1 (fr)
CN (2) CN100351242C (fr)
AP (2) AP1265A (fr)
AR (1) AR018705A1 (fr)
AT (1) ATE348098T1 (fr)
AU (2) AU781402B2 (fr)
BG (1) BG65194B1 (fr)
BR (1) BRPI0001486B8 (fr)
CA (2) CA2302965C (fr)
CO (1) CO5160273A1 (fr)
CR (1) CR6165A (fr)
CZ (1) CZ299426B6 (fr)
DE (1) DE60032275T2 (fr)
DK (1) DK1044969T3 (fr)
DZ (1) DZ3030A1 (fr)
EA (3) EA005892B1 (fr)
EE (1) EE04589B1 (fr)
EG (1) EG22506A (fr)
ES (1) ES2278578T3 (fr)
GE (1) GEP20022653B (fr)
GT (1) GT200000037A (fr)
HR (1) HRP20000182B1 (fr)
HU (1) HU227698B1 (fr)
ID (1) ID25427A (fr)
IL (2) IL168036A (fr)
IS (1) IS2468B (fr)
MA (1) MA25087A1 (fr)
MY (1) MY136270A (fr)
NO (2) NO321952B1 (fr)
NZ (2) NZ503683A (fr)
OA (1) OA11335A (fr)
PA (1) PA8491901A1 (fr)
PE (1) PE20001599A1 (fr)
PL (1) PL339330A1 (fr)
PT (1) PT1044969E (fr)
RS (1) RS49836B (fr)
SG (2) SG121687A1 (fr)
SK (1) SK287339B6 (fr)
SV (1) SV2002000047A (fr)
TN (1) TNSN00064A1 (fr)
TR (1) TR200000837A2 (fr)
TW (1) TW553939B (fr)
UA (2) UA80955C2 (fr)
UY (1) UY26086A1 (fr)
YU (1) YU13200A (fr)
ZA (1) ZA200001586B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
ATE419239T1 (de) 2000-10-20 2009-01-15 Eisai R&D Man Co Ltd Verfahren zur herstellung von 4-phenoxy chinolin derivaten
EP1408980A4 (fr) 2001-06-21 2004-10-20 Ariad Pharma Inc Nouvelles quinazolines et leur utilisation
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP2280003B1 (fr) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Procédé pour la préparation de modulateurs de kinases de type récepteur
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
JPWO2004080462A1 (ja) 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
EP2392565B1 (fr) 2003-09-26 2014-03-19 Exelixis, Inc. Modulateurs de c-Met et procédés d'utilisation
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
NZ550796A (en) * 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
JP4834553B2 (ja) 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
EP1833482A4 (fr) 2005-01-03 2011-02-16 Myriad Genetics Inc Composés bicycliques azotés et utilisation thérapeutique associée
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
US20090047278A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Combinational Use of Sulfonamide Compound
WO2007015569A1 (fr) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. Procédé de prédiction de l’efficacité d’un inhibiteur de vascularisation
EP1925676A4 (fr) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Procédé d'analyse de l' effet d 'un inhibiteur de vascularisation
JPWO2007052849A1 (ja) * 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
WO2007061127A1 (fr) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. Agent antitumeur pour myelomes multiples
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (fr) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Agent thérapeutique contre la fibrose hépatique
EP2054393A1 (fr) 2006-07-28 2009-05-06 Synthon B.V. Forme cristalline d'erlobtinib
US8865737B2 (en) 2006-08-28 2014-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8372856B2 (en) * 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
CN101616671A (zh) 2007-01-19 2009-12-30 卫材R&D管理有限公司 胰腺癌治疗用组合物
WO2008093855A1 (fr) 2007-01-29 2008-08-07 Eisai R & D Management Co., Ltd. Composition destinée au traitement d'un cancer de l'estomac de type indifférencié
ES2573931T3 (es) * 2007-02-21 2016-06-13 Natco Pharma Limited Nuevos polimorfismos de clorhidrato de erlotinib y método de preparación
JP5524041B2 (ja) 2007-04-04 2014-06-18 シプラ・リミテッド エルロチニブおよびその薬学的に許容可能な塩の製造方法
US20090012295A1 (en) * 2007-06-25 2009-01-08 Ales Gavenda Amorphous Erlotinib, processes for the preparation thereof, and processes to prepare additional forms of Erlotinib
WO2009007984A2 (fr) 2007-07-11 2009-01-15 Hetero Drugs Limited Procédé amélioré pour l'hydrochlorate d'erlotinibe
TW200925152A (en) * 2007-08-23 2009-06-16 Plus Chemicals S A Processes for the preparation of crystalline forms A, B and pure crystalline form a of erlotinib HCL
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
WO2009121042A1 (fr) * 2008-03-28 2009-10-01 Concert Pharmaceuticals, Inc. Dérivés de quinazoline et procédés de traitement
KR20110017907A (ko) * 2008-07-07 2011-02-22 플러스 케미칼스, 에스.에이. 엘로티닙 염기 및 엘로티닙 ｈｃｌ의 결정형
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (fr) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Procédés de préparation du chlorhydrate d'erlotinib
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
TH121482A (th) 2009-08-19 2013-02-28 นางสาวปัณณพัฒน์ เหลืองธาตุทอง องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (fr) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration par inhalation de sel de mésylate de n-(3-éthynylphénylamino)-6,7-bis(2-méthoxyéthoxy)-4-quinazolinamine
AU2011270165B2 (en) 2010-06-25 2015-12-24 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2806273A1 (fr) 2010-07-23 2012-03-08 Generics (Uk) Limited Erlotinib pur
IT1402029B1 (it) * 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
WO2012144463A1 (fr) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent thérapeutique pour les tumeurs
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
WO2014118737A1 (fr) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Sels d'erlotinib
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
CA2908441A1 (fr) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Procede de preparation d'erlotinib
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (fr) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Agent therapeutique pour tumeur
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
DE69522717T2 (de) * 1995-03-30 2002-02-14 Pfizer Inc., New York Chinazolinderivate
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP4471404B2 (ja) 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Ｖｅｇｆインヒビターとしてのキナゾリン誘導体
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
TR200003166T2 (tr) 1998-04-29 2001-02-21 Osi Pharmaceuticals, Inc. N-(3-etinilfenilamino)-6, 7-bis(2-metoksietoksi)-4-kuinozolamin mesilat anhidrat ve monohidrat.

Also Published As

Publication number Publication date
CZ299426B6 (cs) 2008-07-23
HRP20000182A2 (en) 2001-04-30
NO321952B1 (no) 2006-07-24
IS2468B (is) 2008-12-15
DK1044969T3 (da) 2007-04-23
JP2000290262A (ja) 2000-10-17
AP1655A (en) 2006-09-01
RS49836B (sr) 2008-08-07
CN100351242C (zh) 2007-11-28
HK1029790A1 (en) 2001-04-12
EP1044969B1 (fr) 2006-12-13
EA200000274A3 (ru) 2003-02-27
ID25427A (id) 2000-10-05
SV2002000047A (es) 2002-01-23
GT200000037A (es) 2001-09-21
JP3420549B2 (ja) 2003-06-23
KR20010014658A (ko) 2001-02-26
AR018705A1 (es) 2001-11-28
UA80955C2 (en) 2007-11-26
CZ20001155A3 (cs) 2001-03-14
PT1044969E (pt) 2007-05-31
CA2427221A1 (fr) 2000-09-30
AP2000001778A0 (en) 2000-03-31
AU2262000A (en) 2000-10-05
DE60032275T2 (de) 2007-07-12
AU2005201494A1 (en) 2005-05-05
CN1699350A (zh) 2005-11-23
PE20001599A1 (es) 2001-01-18
AP1265A (en) 2004-03-26
UY26086A1 (es) 2000-10-31
KR100430209B1 (ko) 2004-05-03
EA200000274A2 (ru) 2000-10-30
NZ503683A (en) 2001-09-28
CN1276370A (zh) 2000-12-13
SK4442000A3 (en) 2000-10-09
EG22506A (en) 2003-03-31
EP1044969A2 (fr) 2000-10-18
AU781402B2 (en) 2005-05-19
SK287339B6 (sk) 2010-07-07
GEP20022653B (en) 2002-03-25
NZ512818A (en) 2003-01-31
BG65194B1 (bg) 2007-06-29
EE200000255A (et) 2000-12-15
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
MY136270A (en) 2008-09-30
CA2302965C (fr) 2004-02-17
BRPI0001486B8 (pt) 2021-05-25
SG121687A1 (en) 2006-05-26
CR6165A (es) 2008-10-10
HU0001353D0 (en) 2000-06-28
NO20001648L (no) 2000-10-02
CA2302965A1 (fr) 2000-09-30
PA8491901A1 (es) 2001-12-14
CA2427221C (fr) 2008-09-16
CO5160273A1 (es) 2002-05-30
US6476040B1 (en) 2002-11-05
SG115536A1 (en) 2005-10-28
EP1044969A3 (fr) 2000-11-29
JP2003176274A (ja) 2003-06-24
ES2278578T3 (es) 2007-08-16
EA005561B1 (ru) 2005-04-28
IL135245A0 (en) 2001-05-20
MA25087A1 (fr) 2000-10-01
YU13200A (sh) 2002-10-18
UA70928C2 (uk) 2004-11-15
TW553939B (en) 2003-09-21
CN1215061C (zh) 2005-08-17
BRPI0001486B1 (pt) 2019-01-29
TR200000837A2 (tr) 2000-11-21
KR20020084903A (ko) 2002-11-13
ZA200001586B (en) 2001-10-01
HUP0001353A2 (hu) 2001-05-28
EA200201244A1 (ru) 2003-04-24
JP4074509B2 (ja) 2008-04-09
KR100430210B1 (ko) 2004-05-03
HUP0001353A3 (en) 2002-01-28
NO20054715L (no) 2000-10-02
EA004654B1 (ru) 2004-06-24
OA11335A (en) 2003-12-10
PL339330A1 (en) 2000-10-09
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
EA200201245A1 (ru) 2003-04-24
HU227698B1 (en) 2011-12-28
NO20001648D0 (no) 2000-03-30
AU2005201494B2 (en) 2008-02-07
ATE348098T1 (de) 2007-01-15
BG104278A (en) 2001-08-31
IS5411A (is) 2000-10-02
DE60032275D1 (de) 2007-01-25
EA005892B1 (ru) 2005-06-30
BR0001486A (pt) 2001-05-02
DZ3030A1 (fr) 2004-03-27

Similar Documents

Publication Publication Date Title
EE04589B1 (et) Vähivastaste ühendite valmistamise protsessid ja vaheühendid
NO20015017D0 (no) Fremgangsmåte for fremstilling av citalopram
NO20010318L (no) Fremgangsmåte for fremstilling av Citalopram
NO20010319L (no) Fremgangsmate for fremstilling av Citalopram
FI20000564A0 (fi) Menetelmä nanolaminaattien valmistamiseksi
PT1210113E (pt) Composicoes de vacinas de combinacao
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20013369D0 (no) Arylpiperazinyl-cykloheksyl-indol-derivater for behandling av depresjon
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
EE04747B1 (et) Amiini-plaatina komplekside valmistamismeetod
FI20011622A0 (fi) Menetelmä sitalopraamin valmistamiseksi
NO20013818D0 (no) Mikrobiell fremgangsmåte for fremstilling av pravastatin
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20003454L (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
EE200000537A (et) Pürasolo[4,3-d]pürimidiin-7-oon-3-püridüülsulfonüülühendite ja nende vaheühendite valmistamise protsess
PT1175417E (pt) Compostos substituidos de benzolactamas
ITMI992048A0 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabi cicloalcani
DK1177165T3 (da) Fremgangsmåde til fremstilling af pesticidmellemprodukter
NO20022956D0 (no) Fremgangsmåte for fremstilling av nitroguanidin
NO20000805D0 (no) Fremgangsmåte for fremstilling av organiske azider
EE200100333A (et) Meetod 2-halo-3-nitro-4-aminopüridiini valmistamiseks ja selleks vajalike vaheühendite saamine
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110330